Statins for primary prevention: at what coronary risk is safety assured?

• Published in: British journal of clinical pharmacology Vol. 52; no. 4; pp. 439 - 446
• Main Authors: Jackson, Peter R., Wallis, Erica J., Haq, Ifti U., Ramsay, Lawrence E.
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Science Ltd 01.10.2001; Blackwell Science; Blackwell Science Inc
• Subjects: Biological and medical sciences; Coronary Disease - etiology; Coronary Disease - mortality; Coronary Disease - prevention & control; drug safety; Female; General and cellular metabolism. Vitamins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use; hydroxymethylglutaryl‐Co A reductase inhibitors; hyperlipidaemia; Hyperlipidemias - complications; Hyperlipidemias - drug therapy; Male; Medical sciences; meta‐analysis; Middle Aged; Pharmacoepidemiology; Pharmacology. Drug treatments; Primary Prevention; Randomized Controlled Trials as Topic; Risk Factors; Human; Enzyme; Treatment efficiency; Coronary artery; Enzyme inhibitor; Cardiovascular disease; Controlled therapeutic trial; Coronary heart disease; Thrombosis; Metaanalysis; Arterial disease; Vascular disease; Prevention; Chemotherapy; Treatment; Placebo; Clinical trial; Hydroxymethylglutaryl-CoA reductase; Oxidoreductases; Comparative study; Bibliographic review; Antilipemic agent

Aims  Increasingly HMG CoA reductase inhibitors (statins) are being used for primary prevention of vascular disease in patients with a raised cholesterol but at low absolute risk of coronary heart disease (CHD). This study uses clinical trial results to explore the limits of absolute safety for stat...